Literature DB >> 8646552

Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs.

B Fang1, H Wang, G Gordon, D A Bellinger, M S Read, K M Brinkhous, S L Woo, R C Eisensmith.   

Abstract

Two recombinant adenoviruses expressing either human alpha 1-antitrypsin (hAAT) or canine factor IX (cFIX) were modified so that they also contained a temperature-sensitive mutation (ts125) in the DNA binding protein encoded within the viral E2A region. The effects of the inclusion of the ts125 mutation on transgene expression in vivo were evaluated in Balb/c mice and hemophilia B dogs by comparison with adenoviral vectors containing the same transgene but lacking the ts125 mutation. No significant differences in the duration of transgene expression were observed in either animal model. Insufficiency of the ts125 mutation in the prolongation of transgene expression in these two animal models suggests that further modification of the vector backbone may be required to achieve long-term gene expression in a wide variety of applications. Additionally, humoral immune response to transgene products has been demonstrated in immunocompetent animal models, which will also need to be surmounted for long-term efficacy in disease treatment by gene therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8646552

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  19 in total

1.  Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill colony.

Authors:  R W Herzog; V R Arruda; T H Fisher; M S Read; T C Nichols; K A High
Journal:  Thromb Haemost       Date:  2000-08       Impact factor: 5.249

2.  Persistence of recombinant adenovirus in vivo is not dependent on vector DNA replication.

Authors:  J E Nelson; M A Kay
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted.

Authors:  H Zhou; W O'Neal; N Morral; A L Beaudet
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

4.  Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers.

Authors:  K Jooss; Y Yang; K J Fisher; J M Wilson
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

5.  Effect of the E4 region on the persistence of transgene expression from adenovirus vectors.

Authors:  D Armentano; J Zabner; C Sacks; C C Sookdeo; M P Smith; J A St George; S C Wadsworth; A E Smith; R J Gregory
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

6.  Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo.

Authors:  D E Brough; C Hsu; V A Kulesa; G M Lee; L J Cantolupo; A Lizonova; I Kovesdi
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

7.  Conditional repression of the E2 transcription unit in E1-E3-deleted adenovirus vectors is correlated with a strong reduction in viral DNA replication and late gene expression in vitro.

Authors:  K Rittner; H Schultz; A Pavirani; M Mehtali
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

8.  Diminishing adenovirus gene expression and viral replication by promoter replacement.

Authors:  B Fang; P Koch; J A Roth
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

Review 9.  Somatic gene therapy for phenylketonuria and other hepatic deficiencies.

Authors:  R C Eisensmith; S L Woo
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

Review 10.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.